What is the recommended Omberacetam (Noopept) dosage?

Omberacetam (Noopept) dosing varies by experience level. Beginners typically start at 10mg daily, moderate users at 10mg 3x daily, and aggressive protocols use 20mg 3x daily.

How do you reconstitute Omberacetam (Noopept)?

Omberacetam (Noopept) comes as a pre-filled device — no reconstitution needed.

What is the half-life of Omberacetam (Noopept)?

The half-life of Omberacetam (Noopept) is ~15-20 min (plasma); active metabolite CPG persists longer. This determines how frequently you need to dose for consistent blood levels.

Omberacetam (Noopept)

CognitiveOralResearchGrade B~15-20 min (plasma); active metabolite CPG persists longer half-life

NootropicDipeptideBDNF EnhancerNGF EnhancerNeuroprotectiveRacetam DerivativeOral8 weeks on / 4 weeks off

Benefits

Increases BDNF and NGF expression in the hippocampus for improved neuroplasticity

Enhances memory consolidation and retrieval

Neuroprotective against oxidative stress and amyloid-beta toxicity

Reduces anxiety and improves emotional stability without sedation

Anti-inflammatory properties in CNS tissue

Rapid oral bioavailability with blood-brain barrier penetration

Approximately 1000x more potent than piracetam by weight

Half-Life

~15-20 min

Route

Oral

Frequency

Daily

Vial Sizes

10mg, 30mg

BAC Water

Pre-filled

Safety Grade

Grade B

Open Omberacetam (Noopept) Dosage Calculator

Calculate exact syringe units for your vial and dose

About Omberacetam (Noopept)

Omberacetam (Noopept, GVS-111) is a synthetic dipeptide nootropic developed in Russia as a cognitive enhancer and neuroprotective agent. Chemically known as N-phenylacetyl-L-prolylglycine ethyl ester, it was designed as a bioavailable prodrug that rapidly crosses the blood-brain barrier after oral administration. Though structurally related to piracetam, omberacetam is estimated to be roughly 1000 times more potent by weight. It acts primarily through modulation of glutamatergic AMPA and NMDA receptors, upregulation of BDNF and NGF expression in the hippocampus, and antioxidant-mediated neuroprotection. Approved in Russia for mild cognitive disorders of vascular and traumatic origin, it has shown improvements in memory, attention, and emotional stability in clinical studies lasting up to 56 days.

Who Should Consider Omberacetam (Noopept)

Adults with mild cognitive disorders of vascular or traumatic origin
Individuals seeking memory and focus enhancement for academic or professional demands
Older adults experiencing age-related cognitive decline
People recovering from traumatic brain injury or concussion
Those looking for a non-stimulant nootropic without addiction potential
Users interested in long-term neuroprotection and neuroplasticity support

How Omberacetam (Noopept) Works

Omberacetam acts as a prodrug that is rapidly metabolized to cycloprolylglycine (CPG), which modulates AMPA and NMDA glutamate receptors to enhance long-term potentiation and synaptic plasticity. It upregulates expression of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) in the hippocampus, promoting neuronal survival and growth. The compound also activates HIF-1 alpha signaling, provides antioxidant protection by reducing reactive oxygen species, inhibits calcium- and glutamate-mediated neurotoxicity, and exerts anti-inflammatory effects in CNS tissue. Unlike piracetam, omberacetam achieves these effects at milligram-level doses due to its high lipophilicity and efficient BBB penetration.

What to Expect

Days 1-3

Some users report improved mental clarity and focus within the first dose due to rapid BBB penetration. Subtle improvements in alertness and verbal fluency. Effects may feel mild compared to stimulants — omberacetam works through gradual neurotrophin upregulation.

Days 4-7

Memory recall and learning speed begin to improve. Anxiolytic effects emerge with reduced emotional reactivity to stress. BDNF and NGF upregulation is underway in the hippocampus.

Weeks 2-4

Peak nootropic effects develop — improved working memory, faster information processing, and better attention span. Dream vividness and sleep quality may increase. Clinical studies show measurable improvement in Mini-Mental State scores by this point.

Weeks 4-8

Full therapeutic benefit. Sustained improvements in cognition, emotional stability, and neuroprotection. BDNF and NGF expression continues to increase with chronic dosing rather than diminishing — no tolerance develops.

After cycling off

Cognitive benefits may persist for several weeks after discontinuation due to structural neuroplastic changes driven by BDNF and NGF. Gradual return to baseline over 2-4 weeks. Cycle can be repeated after a 4-week break.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	10mg	Daily
Moderate	10mg	3x Daily
Aggressive	20mg	3x Daily

Note: Oral dipeptide nootropic (GVS-111). Piracetam-derived but ~1000x more potent by weight. Increases BDNF and NGF expression in hippocampus. Approved in Russia as a prescription nootropic. Take on an empty stomach for best absorption.

How to Inject Omberacetam (Noopept)

Take 10 mg orally or sublingually 2-3 times daily, shortly after meals or on an empty stomach. Sublingual delivery may produce faster onset (~5 min vs ~15 min oral). Do not exceed 30 mg per day. Avoid dosing in the evening to prevent sleep disruption. Co-supplementation with a choline source (alpha-GPC 300 mg or CDP-choline 250 mg) is commonly recommended to reduce headache risk. Tablets can be swallowed whole or dissolved under the tongue. No reconstitution required.

Cycling Protocol

On Period

8 weeks

Off Period

4 weeks

Russian clinical protocols use 56-day (8-week) treatment courses at 20 mg/day. A 4-week washout period is recommended between cycles. Chronic administration does not appear to cause tolerance — BDNF and NGF upregulation actually increases with sustained use. Some users run shorter 4-week cycles with 2-week breaks.

Pharmacokinetics

Half-Life

20min

Bioavailability

Oral: ~7-10% (parent compound); high CNS bioavailability due to rapid BBB penetration

Tmax

~15 min (oral); ~5 min (sublingual)

Data Confidence

moderate

Source: Plasma t½ ~20 min in humans; active metabolite cycloprolylglycine (CPG) has a longer effective duration. Rat pharmacokinetics show t½ ~0.38 h (Boiko et al. 2000 PMID 10977920; Boiko et al. 2018 PMID 30378564)

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Generally well-tolerated at recommended doses. Possible headache (especially without choline co-supplementation), irritability, restlessness, and insomnia if taken late in the day. Occasional GI discomfort. Elevated blood pressure reported rarely. LD50 in rats exceeds 2000 mg/kg oral — approximately 100x therapeutic doses.

Contraindications

Pregnancy or breastfeeding — no safety data available
Known hypersensitivity to omberacetam or racetam-class compounds
Severe hepatic impairment — metabolized via liver esterases
Severe renal impairment — insufficient safety data
Children under 18 — not studied in pediatric populations
Uncontrolled hypertension — rare reports of blood pressure elevation

Drug Interactions

Cholinesterase inhibitors (donepezil, galantamine, rivastigmine) — may potentiate cholinergic effects; increased risk of GI side effects and excessive acetylcholine activity
Glutamatergic drugs (memantine, amantadine) — additive effects on NMDA receptor modulation; use with caution
Anticoagulants (warfarin) — omberacetam may have mild antithrombotic properties; monitor INR if co-administered
CNS stimulants (modafinil, amphetamines) — potential for additive excitatory effects; may increase risk of insomnia or irritability
Alcohol — not recommended; may counteract neuroprotective effects and increase CNS depression
Other racetams (piracetam, aniracetam) — redundant mechanism; co-use offers unclear benefit and increases side effect risk
Benzodiazepines — omberacetam has mild anxiolytic properties that may alter sedation thresholds